Back to search results

EPICkids: Understanding Nutrition and Lifestyle in Childhood Cancer

This study, called EPICkids, is looking at how nutrition and lifestyle affect children and teenagers with acute lymphoblastic leukemia (ALL) and certain brain tumors. Researchers want to understand how what you eat and your daily habits are connected to side effects from treatment and how well you recover. This is an observational study, meaning there are no interventions or treatments being tested; instead, researchers will collect information from participants. You might be able to join if you are between 3 and 21 years old and have a new diagnosis of ALL or a favorable biology brain tumor. The goal is to create a resource that helps us understand the link between nutrition, lifestyle, and outcomes for these conditions.

Study design
This is an observational study planning to enroll 1400 participants. It is not testing a new treatment, but rather collecting information about patients.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Information will be collected from diagnosis up to one year after the end of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05375617

European Prospective Investigation Into Childhood Cancer

Recruiting
Not specifiedAges 3–21Observational
Columbia University
~1,400 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:Observational

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate the association of dietary and lifestyle variables to examine the association of nutritional status and dietary intake with side-effects from treatment and survival in children and adolescents with ALL and favorable biology brain tumors.
Measured over From diagnosis to 1 year post-end of treatment

Conditions

Acute Lymphoblastic Leukemia
Brain Tumor

Explore related trials

Acute Lymphoblastic LeukemiaBrain Neoplasm

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Elena J Ladas, PhD, RD · PRINCIPAL_INVESTIGATOR · Columbia University

Who to contact

Michelle Walters
[email protected]
2128514995
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

ALL: Patients must have newly diagnosed B-cell ALL, T-cell ALL, or mixed phenotype acute leukemia confirmed by immunophenotyping by flow cytometry.
Brain tumors: Patients must have newly diagnosed favorable biology brain tumor confirmed by either pathology report, imaging and/or biochemical studies including low-grade gliomas, medulloblastoma, ependymoma, pituitary tumors, germ cell tumors.
ALL and brain tumors: Participants may be children on a clinical trial or "as per" a clinical trial.
ALL: Patients will receive standard leukemia treatment.
Brain tumors: Patients will be treated depending upon standard approach with surgery, chemotherapy, radiation therapy. Patients receiving autologous stem cell transplantation as part of their regimen may be included.
ALL: Parents/guardians must consent and patient assent, if applicable, within three working days of diagnosis.
Brain tumors: Parents/guardians must consent and assent, if applicable, prior to initiation of chemotherapy, radiation or stem cell transplant.

Exclusion

Patients with relapsed or progressive disease, exclusive of patients with unresectable low-grade gliomas who have progressive disease.
Patients with history of other primary malignancy.
Patients with other medical conditions not associated with the malignancy that may interfere with nutritional status/growth and/or microbiome composition, like patients with Down's syndrome, metabolic disorders or celiac disease. Patients with genetic predisposition that may interfere with nutritional status/growth.
Patient plans to receive hematopoietic stem cell transplant.
Mixed lineage leukemias who receive AML-based protocols. Brain tumors: Children/adolescents who will be managed by observation or surgery only, or diagnosed with ATRT or high-grade gliomas.

What this trial measures

  • Evaluate the association of dietary and lifestyle variables to examine the association of nutritional status and dietary intake with side-effects from treatment and survival in children and adolescents with ALL and favorable biology brain tumors.From diagnosis to 1 year post-end of treatment